These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 18060493

  • 1. Routine prophylactic granulocyte colony stimulating factor (GCSF) is not necessary with accelerated (dose dense) paclitaxel for early breast cancer.
    Arnedos M, Sutherland S, Ashley S, Smith I.
    Breast Cancer Res Treat; 2008 Nov; 112(1):1-4. PubMed ID: 18060493
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Impact of neutropenia on delivering planned chemotherapy for solid tumours.
    Khan S, Dhadda A, Fyfe D, Sundar S.
    Eur J Cancer Care (Engl); 2008 Jan; 17(1):19-25. PubMed ID: 18181887
    [Abstract] [Full Text] [Related]

  • 6. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy.
    Shayne M, Crawford J, Dale DC, Culakova E, Lyman GH, ANC Study Group.
    Breast Cancer Res Treat; 2006 Dec; 100(3):255-62. PubMed ID: 16705366
    [Abstract] [Full Text] [Related]

  • 7. Granulocyte-colony stimulating factors for secondary prevention of leucopenia in patients receiving chemotherapy.
    Lowathanasirikul J, Manusirivithaya S, Tangjitgamol S, Leelahakorn S.
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S47-53. PubMed ID: 17726809
    [Abstract] [Full Text] [Related]

  • 8. Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group.
    Skarlos DV, Timotheadou E, Galani E, Samantas E, Grimani I, Lianos E, Aravantinos G, Xanthakis I, Pentheroudakis G, Pectasides D, Fountzilas G.
    Oncology; 2009 Oct; 77(2):107-12. PubMed ID: 19622901
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer.
    Timmer-Bonte JN, Adang EM, Smit HJ, Biesma B, Wilschut FA, Bootsma GP, de Boo TM, Tjan-Heijnen VC.
    J Clin Oncol; 2006 Jul 01; 24(19):2991-7. PubMed ID: 16682725
    [Abstract] [Full Text] [Related]

  • 10. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM, GEICAM 9906 Study Investigators.
    J Natl Cancer Inst; 2008 Jun 04; 100(11):805-14. PubMed ID: 18505968
    [Abstract] [Full Text] [Related]

  • 11. Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment.
    Symmans WF, Volm MD, Shapiro RL, Perkins AB, Kim AY, Demaria S, Yee HT, McMullen H, Oratz R, Klein P, Formenti SC, Muggia F.
    Clin Cancer Res; 2000 Dec 04; 6(12):4610-7. PubMed ID: 11156210
    [Abstract] [Full Text] [Related]

  • 12. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy.
    Demaria S, Volm MD, Shapiro RL, Yee HT, Oratz R, Formenti SC, Muggia F, Symmans WF.
    Clin Cancer Res; 2001 Oct 04; 7(10):3025-30. PubMed ID: 11595690
    [Abstract] [Full Text] [Related]

  • 13. Is pegfilgrastim safe and effective in congenital neutropenia? An analysis of the French Severe Chronic Neutropenia registry.
    Beaupain B, Leblanc T, Reman O, Hermine O, Vannier JP, Suarez F, Lutz P, Bordigoni P, Jourdain A, Schoenvald M, Ouachee M, François S, Kohser F, Jardin F, Devouassoux G, Bertrand Y, Nove-Josserand R, Donadieu J, French SCN Registry, Service d'Hémato Oncologie Pédiatrique.
    Pediatr Blood Cancer; 2009 Dec 04; 53(6):1068-73. PubMed ID: 19618456
    [Abstract] [Full Text] [Related]

  • 14. Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: an observational retrospective survey.
    Repetto L, CIPOMO investigators.
    Crit Rev Oncol Hematol; 2009 Nov 04; 72(2):170-9. PubMed ID: 19406660
    [Abstract] [Full Text] [Related]

  • 15. Role of granulocyte colony stimulating factor (G-CSF) in chemotherapy induced neutropenia.
    Ghalaut PS, Sen R, Dixit G.
    J Assoc Physicians India; 2008 Dec 04; 56():942-4. PubMed ID: 19322972
    [Abstract] [Full Text] [Related]

  • 16. Feasibility of two dose-dense FEC regimens with growth factor support for adjuvant therapy in patients with early breast cancer: results from a randomised study of the Central European Cooperative Oncology Group (CECOG).
    Kahán Z, Spanik S, Wagnerova M, Skacel T, Planko B, Fitzthum E, Lindner E, Soldatenkova V, Zielinski CC, Brodowicz T.
    Breast Cancer Res Treat; 2008 Dec 04; 112(3):557-63. PubMed ID: 18189160
    [Abstract] [Full Text] [Related]

  • 17. The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients.
    Zielinski CC, Awada A, Cameron DA, Cufer T, Martin M, Aapro M.
    Eur J Cancer; 2008 Feb 04; 44(3):353-65. PubMed ID: 18191396
    [Abstract] [Full Text] [Related]

  • 18. Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study.
    Barroso-Sousa R, Paes FR, Vaz-Luis I, Batista RB, Costa RB, Losk K, Camuso K, Metzger-Filho O, Hughes ME, Bunnell CA, Golshan M, Winer EP, Lin NU.
    Breast; 2016 Dec 04; 30():136-140. PubMed ID: 27721193
    [Abstract] [Full Text] [Related]

  • 19. Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial.
    Loibl S, Murmann C, Schwedler K, Warm M, Müller L, Heinrich G, Nekljudova V, von Minckwitz G.
    Cancer Chemother Pharmacol; 2009 Apr 04; 63(5):953-8. PubMed ID: 18716777
    [Abstract] [Full Text] [Related]

  • 20. Recombinant human granulocyte colony stimulating factor in patients with systemic lupus erythematosus associated neutropenia and refractory infections.
    Euler HH, Harten P, Zeuner RA, Schwab UM.
    J Rheumatol; 1997 Nov 04; 24(11):2153-7. PubMed ID: 9375876
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.